Development of novel benzamide class I selective lysine deacetylase inhibitors as potent anticancer agents

Small molecule inhibitors of lysine deacetylases (KDACs), exemplified by histone deacetylases (HDACs), exhibit significant promise as cancer therapeutics. Using a modular combinatorial chemistry approach, a novel class of KDAC inhibitors (KDACi) containing the aminophenyl-benzamide headgroup have be...

Full description

Saved in:
Bibliographic Details
Main Authors: Jason H. Gill, Jonathan D. Sellars, Paul G. Waddell, Steven D. Shnyder, Ronald Grigg, Colin W. G. Fishwick
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/14756366.2025.2520612
Tags: Add Tag
No Tags, Be the first to tag this record!